ADRIATIC: Outcomes in long-term progression-free LS-SCLC survivors treated with durvalumab are associated with molecular characteristics of the tumor microenvironment

ESMO 2024

Lung, Respiratory and Thoracic Cancer

ADRIATIC: Subgroups analyses further support durvalumab consolidation as a new standard of care in LS-SCLC

Genitourinary Cancer

Long-term outcomes and patterns of relapse in patients with bilateral Wilms tumor or bilaterally predisposed unilateral Wilms tumor, a report from the COG AREN0534 study

Int J Cancer

Murphy AJ, Brzezinski J, Renfro LA, Tornwall B, Malek MM, Benedetti DJ, Cost NG, Smith EA, Aldrink J, Romao RLP, Dome JS, Davidoff AM, Treece AL, Parsons LN, Mullen EA, Shamberger RC, Paulino AC, Lo AC, Geller JI, Ehrlich PF

doi: 10.1002/ijc.35080

Lung, Respiratory and Thoracic Cancer

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Lung Cancer

Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H

doi: 10.1016/j.lungcan.2024.108056

Lymphoma

Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma

Blood Cancer J

Larocca C, Bui AN, O'Malley JT, Giobbie-Hurder A, Tawa M, Teague JE, Clark RA, Cutler C, Jacobsen E, Fisher DC, Kupper TS, LeBoeuf NR

doi: 10.1038/s41408-025-01237-5

EHA 2025

Multiple Myeloma (MM)

CARTITUDE-1: Cilta-cel achieves long-term treatment-free remission in heavily pretreated patients with RRMM

Central Nervous System Tumors

Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study

J Clin Oncol

Westerveld ASR, Tytgat GAM, van Santen HM, van Noesel MM, Loonen J, de Vries ACH, Louwerens M, Koopman MMW, van der Heiden-van der Loo M, Janssens GO, de Krijger RR, Ronckers CM, van der Pal HJH, Kremer LCM, Teepen JC

doi: 10.1200/JCO.23.01430

Skin Cancer

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

Eur J Cancer

Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, Lawless A, Czapla J, Sullivan RJ, Albrecht LJ, Zimmer L, Mangana J, Dummer R, Kessels JI, Neyns B, Allayous C, Lebbe C, Boatwright C, Mehnert JM, Ottaviano M, Ascierto PA, Czarnecka AM, Rutkowski P, Lo SN, Long GV, Menzies AM, Carlino MS

doi: 10.1016/j.ejca.2024.115171

Skin Cancer

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

Eur J Cancer

Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA

doi: 10.1016/j.ejca.2024.115119

Central Nervous System Tumors

Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa - Results of the HIT 2000 trial

Neuro Oncol

Mynarek M, Rossius A, Guiard A, Ottensmeier H, von Hoff K, Obrecht-Sturm D, Bußenius L, Friedrich C, von Bueren AO, Gerber NU, Traunwieser T, Kortmann RD, Warmuth-Metz M, Bison B, Thomale UW, Krauss J, Pietsch T, Clifford SC, Pfister SM, Sturm D, Sahm F, Tischler T, Rutkowski S

doi: 10.1093/neuonc/noae092

Related content